Cim Lowers stake in Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp (EW) : Cim reduced its stake in Edwards Lifesciences Corp by 20.5% during the most recent quarter end. The investment management company now holds a total of 89,169 shares of Edwards Lifesciences Corp which is valued at $10,343,604 after selling 22,990 shares in Edwards Lifesciences Corp , the firm said in a disclosure report filed with the SEC on Oct 17, 2016.Edwards Lifesciences Corp makes up approximately 4.94% of Cim’s portfolio.

Other Hedge Funds, Including , Cupps Capital Management reduced its stake in EW by selling 40,437 shares or 63.52% in the most recent quarter. The Hedge Fund company now holds 23,227 shares of EW which is valued at $2,818,829. Edwards Lifesciences Corp makes up approx 1.22% of Cupps Capital Management’s portfolio.Cutler Group Lp reduced its stake in EW by selling 17,659 shares or 77.01% in the most recent quarter. The Hedge Fund company now holds 5,271 shares of EW which is valued at $639,689. Edwards Lifesciences Corp makes up approx 0.04% of Cutler Group Lp’s portfolio.First Mercantile Trust Co reduced its stake in EW by selling 724 shares or 4.12% in the most recent quarter. The Hedge Fund company now holds 16,865 shares of EW which is valued at $2,025,318. Edwards Lifesciences Corp makes up approx 0.27% of First Mercantile Trust Co’s portfolio. Central Bank Trust Co added EW to its portfolio by purchasing 88 company shares during the most recent quarter which is valued at $10,568.

Edwards Lifesciences Corp closed down -2.66 points or -2.24% at $116 with 20,14,131 shares getting traded on Friday. Post opening the session at $118.56, the shares hit an intraday low of $115.95 and an intraday high of $119.17 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 115 from a previous price target of $100 .Company shares were Reiterated by Canaccord Genuity on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 140 from a previous price target of $132 .Company shares were Reiterated by Leerink Partners on Jul 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 130 from a previous price target of $125 .

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Edwards Lifesciences Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Edwards Lifesciences Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.